| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4744533
Max Phase: Preclinical
Molecular Formula: C14H18N2O2S
Molecular Weight: 278.38
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: Cc1cc(C)cc(NC(=O)[C@@H]2CSCCC(=O)N2)c1
Standard InChI: InChI=1S/C14H18N2O2S/c1-9-5-10(2)7-11(6-9)15-14(18)12-8-19-4-3-13(17)16-12/h5-7,12H,3-4,8H2,1-2H3,(H,15,18)(H,16,17)/t12-/m0/s1
Standard InChI Key: CETUQXRBHGMESF-LBPRGKRZSA-N
Associated Targets(non-human)
Metabotropic glutamate receptor 4 663 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 278.38 | Molecular Weight (Monoisotopic): 278.1089 | AlogP: 1.86 | #Rotatable Bonds: 2 |
| Polar Surface Area: 58.20 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 11.41 | CX Basic pKa: | CX LogP: 1.97 | CX LogD: 1.97 |
| Aromatic Rings: 1 | Heavy Atoms: 19 | QED Weighted: 0.87 | Np Likeness Score: -1.19 |
References
| 1. Kent CN,Fulton MG,Stillwell KJ,Dickerson JW,Loch MT,Rodriguez AL,Blobaum AL,Boutaud O,Rook JL,Niswender CM,Conn PJ,Lindsley CW. (2021) Discovery and optimization of a novel CNS penetrant series of mGlu PAMs based on a 1,4-thiazepane core with in vivo efficacy in a preclinical Parkinsonian model., 37 [PMID:33556572] [10.1016/j.bmcl.2021.127838] |
Source
Source(1):